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The classification of liposarcoma has evolved significantly over past several decades, in large 
part owing to the advances in our understanding of its molecular genetics. It is now clear that 
liposarcomas cluster into 3 main subtypes consisting of: atypical lipomatous tumor-well 
differentiated liposarcoma (WDLPS) (lipoma-like, sclerosing and 
inflammatory)/dedifferentiated liposarcoma (DDLPS), myxoid/round cell liposarcoma 
(MLPS) and pleiomorphic liposarcoma (PLPS).  
WDLPS/DDLPS 
A characteristic feature of WDLPS/DDLPS is the presence of supernumary ring and/or giant 
rod chromosomes containing amplified segments from the 12q13-15 region that can be 
identified by fluorescence in situ hybridization (FISH) and comparative genomic 
hybridization (CGH). Intensive research has identified several oncogenes residing in this 
region, including MDM2, CDK4, HMGA2, TSPAN31 (SAS), YEATS4, CPM, OS1, OS9, 
CHOP and GLI1. The most evidence to date demonstrates an oncogenic role in 
WDLPS/DDLPS for MDM2, CDK4, HMGA2 and TSPAN31 (SAS). Recently Wang et al. 
(Genes, Chromosomes & Cancer, 2011) described consistent amplification of the Fibroblast 
Growth Factor Receptor Substrate 2 Gene (FRS2) in WDLPS and DDLPS. MDM2 is the 
most frequent amplification (close to 100%) however CDK4 is shown to be amplified in over 
90% of cases. Co-amplification of MDM2 and CDK4 is a common feature and may result in 
proliferation through combined effects upon p53 (by inactivating TP53) and the cell cycle (by 
RB1 phosphorylation). The corresponding proteins are potential therapeutic targets (Singer et 
al.; Cancer Res, 2007). Interestingly, the rearrangements of chromosome 12 on the giant rod 
chromosome are discontinuously and MDM2 and CDK4 may belong to different amplicons. 
It has been suggested that CDK4 provides a selection advantage in WDLPS/DDLPS and may 
contribute to transformation as CDK4 negative WDLPS exhibit more favourable prognostic 
features (Italiano A et al.; Clin Cancer Res, 2009). Louis Brennetat et al. (Genes, 
Chromosomes & Cancer, 2011) demonstrate that an alteration of the 
CDKN2A/CDKN2B/CDK4/CCND1 pathway in almost all cases without CDK4 amplification 
compensate for the lack of CDK4 expression, theraby confirming the pivotal role of this 
pathway in liposarcoma oncogenesis. A recent study by Thway et al. (Am J Surg Pathol 2012) 
have suggested that the immunohistochemical trio of CDK4, MDM2 and the cell cycle 
regulator p16 is a useful ancillary diagnostic tool distinguishing atypical lipomatous tumor-
WDLPS from benign neoplasms and DDLPS from pleiomorphic and myxoid liposarcomas. 
Well differentiated spindle cell liposarcomas represent a rare atypical/low-grade malignant 
lipogenic neoplasm that has been regarded as a variant of atypical lipomatous tumor. Mentzel 
et al. (Modern Pathology, 2010) have speculated on the basis of clinicopathologic and 
molecular findings (FISH analysis showed RB 1 deletion and no MDM2 amplification) that 
well-differentiated spindle cell liposarcoma may constitute an independent entity rather than a 
morphologic variant of atypical lipomatous tumor, and may represent the atypical/low-grade 
counterpart of spindle cell lipoma. 
Dedifferentiated areas in DDLPS exhibit a wide morphological spectrum (Coindre et al.; 
Virchows Arch, 2010). Epithelial-like pattern composed of undifferentiated large round cells 
resembling a carcinoma or melanoma, areas with dense amianthoid-like fibers and areas 
composed of hibernoma-like cells have been described. The concept of dedifferentiation 
has undergone an evolution in the last several years. Where it was once assumed that all 
dedifferentiated tumors manifested themselves as high grade, undifferentiated sarcoma-like 
lesions, the concept of low grade dedifferentiation has increasingly been recognized, with 
areas resembling low grade myxofibrosarcoma, fibromatosis, well differentiated fibrosarcoma 
and even dermatofibrosarcoma protuberans. Low grade patterns of “neural-like”, 
“meningothelial-like” and “paraganglioma-like” histologies have recently been described. The 
significance of this lower grade of progression is to date, not completely known. However, 
there is some suggestion that the lower grade progression carries a better prognosis than the 
high grade undifferentiated type of DDLPS. In about 5-10% of cases, the dedifferentiated 
component shows divergent differentiation featuring myogenic, angiosarcomatous or 
osteochondromatous components. The presence of a divergent differentiation does not affect 
the clinical outcome. The mechanisms responsible for progression from WDLPS to DDLPS 
are incompletely understood. Recent studies into the WDLPS de-differentiation process have 
suggested a role for c-Jun N-terminal kinase (JNK) pathway (Snyder et al.; J Pathol, 2009). 
Co-amplification of 1p32 and 6q23 that contain c-Jun and Apoptosis Signaling Kinase 1 
(ASK1) are seen in DDLPS but not in WDLPS. Crago et al. (Clin Cancer Res; 2012) have 
described that copy number losses define subgroups of dedifferentiated liposarcoma with poor 
prognosis and genomic instability. In DDLPS loss of 11q23-24 is associated with genomic 
complexity and distinct morphology whereas loss of 19q13 predicts poor prognosis. 
MLPS 
MLPS is the second most common subtype and is characterized by the recurrent translocation 
t(12;16)(q13;p11), resulting in the FUS-CHOP gene fusion (95% of cases) and in rare cases a 
t(12;22)(q13;q12) resulting in the EWS-CHOP gene fusion. The exact function of this 
molecular deregulation and the mechanism by which it contributes to tumorogenesis are 
currently not fully elucidated. FUS-CHOP has been shown to induce adipogenic 
differentiation blockage and cell cycle evasion. Downstream targets of FUS-CHOP (DDIT3) 
include PPARγ2 and C/EBPα (Pérez-Mancera et al.; PLoS One, 2008). Recently evidence 
has indicated a role for the PI3K/Akt pathway in myxoid to round cell progression via 
activating mutation of PIK3CA, loss of PTEN, or IGF1R expression (Demicco et al.; Modern 
Pathology,  2012). The PI3K/Akt pathway may therefore a therapeutic target in round cell 
liposarcoma. The morphologic spectrum of myxoid liposarcoma is broad and often 
underappreciated. Fritchie et al. (Am J Clin Pathol, 2012) described different patterns 
including the traditional myxoid, traditional round cell, pseudoacinar, lipoblast-rich, 
lipomatous, stroma hyalinization, cord-like, chondroid metaplasia, hemangiopericytoma-like, 
island and nested. Island and nested patterns had not previously been described. 
PLPS 
Molecular studies are limited by the scarcity of this disease. Tumors tend to show complex 
arrangements. Taylor et al. (PLoS One, 2008) described that 60% of PLPS have a deletion of 
13q14.2-q14.3, a region that includes the tumor suppressor RB1. Mitotic Arrest Deficient 2 
(MAD2), amplified in PLPS, may also play a critical role. Additional deletions described in 
PLPS include 17p13 and 17q11.2, where p53 and the sarcoma associated tumor suppressor 
gene, neurofibromatosis type 1 (NF1) are located. Barretina et al. (Nat Genet, 2010) showed 
16,7% of PLPS cases had mutations identified in p53 which are rarely seen in MLPS and 
WDLPS/DDLPS. 
“Mixed type” liposarcoma 
Given the advances in the classification of liposarcoma and the extensive cytogenetic and 
molecular characterization of the subtypes of LS, the true mixed lesion represents an enigma. 
It has become increasingly apparent that the so-called mixed type liposarcoma does not exist 
as a distinct entity (Boland et al; Am J Surg Pathol, 2010) (de Vreeze et al.; Int J Cancer, 
2011) and should not be regarded as collision tumors, but as an extreme variant of the 
morphologic spectrum within a single biologic entity. This is shown by different cases 
previously reported as mixed WDLPS and MLPS, which are now considered to represent 
extensively myxoid variants of WDLPS; by cases previously reported as mixed MLPS and 
PLPS in children which appear instead to represent a distinctive pediatric “pleiomorphic 
myxoid liposarcoma” (Alaggio et al.; Am J Surg Pathol, 2009) and by cases of PLPS arising 
in association with WDLPS representing tumors closely related to classic DDLPS (Marino-
Enriquez et al.; Am J Surg Pathol, 2010) (Boland et al.; Am J Surg Pathol, 2010). 
